#USA #Austin #Vivistim #MicroTransponder #VNS Therapy

MicroTransponder’s Medicare Payment Change for Vivistim® Procedure

In a major development for stroke recovery, MicroTransponder®, Inc., a trailblazer in medical technology, has announced that the Centers for Medicare and Medicaid Services (CMS) has classified the Vivistim® procedure under the New Technology Ambulatory Payment Classification (APC) 1580. This change, effective from January 1, 2026, brings with it a national average payment rate of approximately $45,000 for facilities that administer this innovative treatment in an outpatient setting.

This decision by CMS is a significant stride in financial accessibility for patients undergoing the Vivistim® procedure, which utilizes the Vivistim® Paired VNS™ Therapy. Richard Foust, the President and CEO of MicroTransponder, expressed his gratitude for this ruling, highlighting its importance in ensuring adequate reimbursement for the pioneering therapy. Foust mentioned, "This decision reinforces the significant advantages provided by Vivistim Paired VNS Therapy and acknowledges the pressing clinical demand it addresses in stroke recovery."

The Vivistim® Paired VNS™ Therapy stands out as the first FDA-approved intervention specifically designed to enhance upper limb function in individuals who have experienced chronic ischemic stroke. By integrating targeted vagus nerve stimulation with structured functional tasks, this therapy fosters neuroplasticity, which is the brain's ability to reorganize and form new neural connections, ultimately leading to substantial improvements in motor abilities.

The adjustment to Medicare's payment system is particularly essential for hospitals and healthcare providers since it allows them to sustainably offer this advanced therapy. This move aims to broaden access for Medicare beneficiaries, allowing them to receive cutting-edge stroke recovery treatments at reputable medical facilities across the nation.

The announcement is expected to significantly impact the lives of countless stroke survivors who are seeking effective rehabilitation solutions. MicroTransponder, with its commitment to transforming recovery experiences, continues to be a pivotal player in the field of stroke rehabilitation technology.

For healthcare professionals and providers interested in learning more about the Vivistim® Paired VNS™ System, additional resources, including clinical research and safety information, are available at Vivistim.com/health-pros.

In summary, MicroTransponder's achievements underline the ongoing evolution of treatment options available for stroke survivors. The bolstered Medicare coverage not only encourages hospitals to adopt the Vivistim® procedure but also assures patients that innovative healthcare practices are becoming more accessible. This is a hopeful development for many who are striving to regain their independence following a stroke, making the prospect of recovery through advanced technology even brighter.